-

11:17:15 PM

RYTM Stock News

RYTM - Rhythm Pharmaceuticals Inc.

12/01/22 8:00 AM

Nasdaq : RYTM

conferences

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway

RHEA-AI

neutral

11/08/22 7:05 AM

Nasdaq : RYTM

clinical trial

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical

RHEA-AI

neutral

11/08/22 7:00 AM

Nasdaq : RYTM

earnings

Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update

Setmelanotide received FDA

RHEA-AI

neutral

11/07/22 4:01 PM

Nasdaq : RYTM

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway

RHEA-AI

neutral

11/03/22 8:00 AM

Nasdaq : RYTM

Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®

84% of patients with BBS in Phase 3 clinical trial showed clinical benefit of improvement in one

RHEA-AI

neutral

11/02/22 7:30 AM

Nasdaq : RYTM

clinical trial

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023

Long-term data show sustained and increasing

RHEA-AI

neutral

11/01/22 8:00 AM

Nasdaq : RYTM

Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway

RHEA-AI

neutral

10/25/22 8:00 AM

Nasdaq : RYTM

conferencesclinical trial

Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company

RHEA-AI

neutral

10/12/22 8:00 AM

Nasdaq : RYTM

Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022

BOSTON, Oct. 12, 2022 (GLOBE

RHEA-AI

neutral

10/06/22 4:02 PM

Nasdaq : RYTM

managementclinical trial

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

RYTM Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.rhythmtx.com
CeoHunter Smith
Security nameRhythm Pharmaceuticals Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees90
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address222 Berkeley St Fl 12
StateMassachusetts
CityBoston
Zip02116-3733
CountryUS
Phone18572644280

About Rhythm Pharmaceuticals Inc.

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. Rhythm is developing setmelanotide for the treatment of rare genetic diseases of obesity that arise due to an impaired pathway, as setmelanotide has shown the potential to restore impaired pathway function.